Skip to Content

Join the 'Pediatrics' group to help and get support from people like you.

Pediatrics News

Related terms: Pediatrician

Many Parents Unaware of Emergency Plans at Kids' Pre-schools

Posted 30 Oct 2015 by Drugs.com

FRIDAY, Oct. 30, 2015 – Many American parents don't know if their pre-school or child care facility has an emergency plan in place, a new poll finds. Thirty-nine percent of parents with kids aged 5 and younger said their child's pre-school or day care had an emergency during the past two years due to severe weather, a power outage, an evacuation or a violent situation. But only 37 percent of parents knew that emergency plans were available online and only 39 percent said their center has a way to identify kids if an evacuation was needed. Forty percent of parents said their center has enough car seats or vehicles to carry out an evacuation, and 63 percent said their center has a way to confirm the identify of adults picking up kids during an emergency. Further, 65 percent said their center stores emergency contact and health information digitally for easy access when needed, the same ... Read more

Related support groups: Emergency, Pediatrics

Breast Milk Bought Online Might Contain Cow's Milk, Study Finds

Posted 6 Apr 2015 by Drugs.com

MONDAY, April 6, 2015 – Parents who buy breast milk online may not always get 100 percent human milk. A new study found about 10 percent of samples tested were contaminated with cow's milk. "Human milk may be purposely 'topped off' with cow's milk or infant formula, and this could be harmful to babies receiving the purchased milk if they have cow's milk allergy or intolerance," said lead author Sarah Keim, a researcher at Nationwide Children's Hospital in Columbus, Ohio. "For other babies, cow's milk is not recommended as a primary source of nutrition because it does not provide complete nutrition for human infants," Keim said. For the study, published online April 6 in the journal Pediatrics, researchers bought 102 samples of advertised human milk online and tested the DNA in each one. They found that 10 samples contained at least 10 percent of cow's milk. The study authors noted that ... Read more

Related support groups: Breastfeeding, Pediatrics, Breast Milk

FDA Approves Cholbam (cholic acid) for Rare Bile Acid Synthesis Disorders

Posted 17 Mar 2015 by Drugs.com

March 17, 2015 – Today the U.S. Food and Drug Administration approved Cholbam (cholic acid) capsules, the first FDA approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders (including Zellweger spectrum disorders). Patients with these rare, genetic, metabolic conditions exhibit manifestations of liver disease, steatorrhea (presence of fat in the stool) and complications from decreased fat-soluble vitamin absorption. Individuals with these rare disorders lack the enzymes needed to synthesize cholic acid, a primary bile acid normally produced in the liver from cholesterol. The absence of cholic acid in these patients leads to reduced bile flow, accumulation of potentially toxic bile acid intermediates in the liver (cholestasis), and malabsorption of fats and fat-soluble vitamins in ... Read more

Related support groups: Liver Disease, Pediatrics

FDA Approves Unituxin (dinutuximab) for Pediatric High-Risk Neuroblastoma

Posted 10 Mar 2015 by Drugs.com

On March 10, 2015, the U. S. Food and Drug Administration approved dinutuximab (Unituxin, United Therapeutics Corporation), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Dinutuximab is a chimeric monoclonal antibody (also known as ch 14.18), composed of a combination of mouse and human DNA. The approval was based on demonstration of improved event-free survival (EFS) and overall survival (OS) in a multicenter, open-label, randomized trial conducted by the Children’s Oncology Group. Prior to enrollment, patients had achieved at least a partial response to prior therapy for newly diagnosed high-risk neuroblastoma, consisting of induction c ... Read more

Related support groups: Pediatrics, Neuroblastoma

Ask a Question